Single chain variable fragment anti-CD133 antibodies and uses thereof
Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.
1. The hybridoma identified herein as Hybridoma Clone 7.
2. The monoclonal antibody produced by Hybridoma Clone 7.
3. A single-chain variable-fragment (scFv) constructed from a monoclonal antibody produced by Hybridoma Clone 7, wherein the scFv comprises the amino acid sequence of SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:58.
4. The scFv of claim 3 wherein the scFv comprises the amino acid sequence of SEQ ID NO:58.
5. A composition comprising the monoclonal antibody of claim 2 .
6. A composition comprising the scFv of claim 3 .
7. A fusion polypeptide comprising:
a targeting moiety comprising the monoclonal antibody produced by Hybridoma Clone 7 or a single-chain variable-fragment (scFv) thereof; and
a toxin moiety comprising a therapeutically active portion of a cytolytic toxin.
8. The fusion polypeptide of claim 7 wherein the toxin moiety is deimmunized.
9. A composition comprising:
a first fusion polypeptide of claim 7 ; and
a second fusion polypeptide comprising:
a second fusion polypeptide of claim 7 or
a fusion polypeptide comprising a monoclonal antibody or scFv thereof that specifically binds to a second marker differentially expressed by cancer stem cells.
10. The composition of claim 9 wherein the second marker differentially expressed by cancer stem cells comprises CD133.
11. The composition of claim 9 wherein the second marker differentially expressed by cancer stem cells comprises EGFR.
12. A method comprising:
administering to a subject in need of such treatment a therapeutically effective amount of:
the monoclonal antibody produced by Hybridoma Clone 7 or a single-chain variable-fragment (scFv) thereof;
a fusion polypeptide comprising:
a targeting moiety comprising the monoclonal antibody produced by Hybridoma Clone 7 or a single-chain variable-fragment (scFv) thereof; and
a toxin moiety comprising a therapeutically active portion of a cytolytic toxin; or
a composition comprising the monoclonal antibody produced by Hybridoma Clone 7, a scFv thereof, or the fusion polypeptide.
13. The composition of claim 5 further comprising a nanoparticle coupled to the monoclonal antibody.
14. The composition of claim 6 further comprising a nanoparticle coupled to the scFv.
15. A composition comprising;
a detectable marker coupled to:
the monoclonal antibody produced by Hybridoma Clone 7 or a single-chain variable-fragment (scFv) thereof.
16. A method comprising:
contacting the composition of claim 15 with at least one cell that expresses CD133; and
detecting a complex comprising at least a portion of the composition specifically bound to the at least one cell that expresses CD133.
17. The method of claim 16 wherein the contacting comprises administering the composition to a subject comprising cancer stem cells that express CD133.
18. The method of claim 17 wherein detecting a complex comprising at least a portion of the composition specifically bound to the at least one cell that expresses CD133 indicates that the subject has or is at risk of having a neoplastic condition.